A Study of Zidovudine in the Prevention of HIV Infection in Individuals Exposed to the Virus
Status:
Completed
Trial end date:
2005-01-01
Target enrollment:
Participant gender:
Summary
To prevent individuals who have had a massive accidental exposure to HIV from becoming
infected with HIV and possibly developing AIDS, by treating them with zidovudine (AZT).
Although the number of persons who have been (or will be) exposed to a high concentration of
HIV is quite small, these persons have a high risk of becoming infected and treatments are
needed to prevent infection after such an exposure. In animal studies, AZT has prevented the
development of infections after exposure of the animals to a retrovirus (the HIV is a
retrovirus). In patients with AIDS, AZT has been effective in delaying the progression of the
disease. For these reasons a trial of AZT is indicated.
Phase:
N/A
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)